OBJECTIVES: Tildrakizumab is an anti–interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. We report improvement in work productivity and reduced activity impairment from the Week 28 interim analysis of a real-world study of patients with psoriasis treated with tildrakizumab.

METHODS: In the Phase 4, uncontrolled, open-label, real-world study (NCT03718299), patients with moderate-to-severe plaque psoriasis received tildrakizumab 100 mg at Weeks 0, 4, and every 12 weeks thereafter. For this interim analysis, change in work productivity and activity impairment from baseline to Week 28 was measured using the Work Productivity and Activity Impairment questionnaire-Psoriasis (WPAI-PSO), which includes absenteeism, presenteeism, total activity impairment, and work productivity activity impairment domains. Lower scores in the WPAI-PSO questionnaire indicate improved productivity and reduced impairment. Missing data were not imputed.

RESULTS: Of 55 patients enrolled, 52 were assessed at Week 28; 50.9% were male and 94.5% were white, with mean±standard deviation (SD) age 48.6±15.3 years. At Week 28, patients receiving tildrakizumab had significant improvements in all WPAI-PSO domains except for absenteeism, where the mean±SD score was 1.1±5.7 at baseline and decreased to 0.0±0.0 at Week 28 (mean percentage change, −100.0%; P=0.33). The mean±SD presenteeism score decreased from 20.5±21.7 at baseline to 4.0±8.1 (mean percentage change, −85.3%; P<0.001). Total activity impairment score (mean±SD) was 4.5±9.1 at Week 28 compared with 29.5±26.6 at baseline, a mean percentage change of −90.2% (P<0.001). Finally, mean±SD work productivity activity impairment score decreased from 20.9±22.2 at baseline to 4.0±8.1 at Week 28 (mean percentage change, −85.3%; P<0.001).

CONCLUSIONS: In this interim analysis, tildrakizumab treatment significantly improved patient-reported presenteeism, total activity impairment, and work productivity impairment in patients with moderate to severe plaque psoriasis in a real-world setting. The effect of treatment on absenteeism was difficult to interpret due to the low baseline score.